Why the study?
Eliminating or reducing modifiable CVD risk factors and undertaking health-promoting behaviors form the basis of prevention, but their association with quality of life needed evaluation.
Does controlling CVD risk factors and undertaking health-promoting behaviors improve quality of life in patients without a history of CVD?
Does controlling CVD risk factors and undertaking health-promoting behaviors improve quality of life in patients without a history of CVD?
Controlling cardiovascular risk factors and engaging in health-promoting behaviors is associated with significantly better quality of life in patients without prior cardiovascular disease.
(1) Background: Eliminating or reducing the severity of modifiable risk factors of cardiovascular disease (CVD) and undertaking health-promoting behaviors is the basis for prevention. (2) Methods: This study included 200 subjects without a history of CVD, aged 18 to 80 years, who had been diagnosed with hypertension, hypercholesterolemia, or diabetes 6 to 24 months before study enrolment. (3) Results: The median 10-year CV risk assessed by the SCORE2 and SCORE2-OP algorithms was 3.0 (IQR 1.5–7.0). An increase in mean cardiovascular risk in the range from low and moderate to very high was associated with a decrease in quality of life both in individual subscales and the overall score. The median number of controlled risk factors was 4.0 (IQR 3.0–5.0). As the mean number of controlled risk factors increased, the quality of life improved in both of HeartQoL questionnaire subscales (emotional p = 0.0018; physical p = 0.0004) and the overall score (global p = 0.0001). The median number of reported health-promoting behaviors undertaken within 3 years before study enrolment was 3.0 (IQR 2.0–4.0). The highest quality of life in each of the studied dimensions was found in people who reported undertaking three health-promoting behaviors. (4) Conclusions: Controlling CVD risk factors and undertaking health-promoting behaviors has a positive impact on the quality of life of patients without a history of atherosclerotic CVD.
No takes yet. Share an insight, caveat, or question.
Kosobucka et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: